149 related articles for article (PubMed ID: 24630948)
1. Influence of K-ras status and anti-tumour treatments on complications due to colorectal self-expandable metallic stents: a retrospective multicentre study.
Fuccio L; Correale L; Arezzo A; Repici A; Manes G; Trovato C; Mangiavillano B; Manno M; Cortelezzi CC; Dinelli M; Cennamo V; de Bellis M;
Dig Liver Dis; 2014 Jun; 46(6):561-7. PubMed ID: 24630948
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.
Scartozzi M; Mandolesi A; Giampieri R; Pierantoni C; Loupakis F; Zaniboni A; Galizia E; Giustini L; Silva RR; Bisonni R; Berardi R; Biagetti S; Menzo S; Falcone A; Bearzi I; Cascinu S
Int J Cancer; 2010 Oct; 127(8):1941-7. PubMed ID: 20099280
[TBL] [Abstract][Full Text] [Related]
3. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.
Larsen FO; Pfeiffer P; Nielsen D; Skougaard K; Qvortrup C; Vistisen K; Fromm AL; Jørgensen TL; Bjerregaard JK; Hoegdall E; Jensen BV
Acta Oncol; 2011 May; 50(4):574-7. PubMed ID: 21529301
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
Ku GY; Haaland BA; de Lima Lopes G
Cancer Chemother Pharmacol; 2012 Aug; 70(2):231-8. PubMed ID: 22699811
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab plus chemotherapy as first-line treatment for metastatic colorectal cancer: effect of KRAS mutation on treatment efficacy in Taiwanese patients.
Chen MC; Chiang FF; Wang HM
Neoplasma; 2013; 60(5):561-7. PubMed ID: 23790176
[TBL] [Abstract][Full Text] [Related]
8. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
[TBL] [Abstract][Full Text] [Related]
9. Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.
Chang SC; Denne J; Zhao L; Horak C; Green G; Khambata-Ford S; Bray C; Celik I; Van Cutsem E; Harbison C
Clin Colorectal Cancer; 2013 Sep; 12(3):195-203.e2. PubMed ID: 23978462
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.
Saltz L; Badarinath S; Dakhil S; Bienvenu B; Harker WG; Birchfield G; Tokaz LK; Barrera D; Conkling PR; O'Rourke MA; Richards DA; Reidy D; Solit D; Vakiani E; Capanu M; Scales A; Zhan F; Boehm KA; Asmar L; Cohn A
Clin Colorectal Cancer; 2012 Jun; 11(2):101-11. PubMed ID: 22055112
[TBL] [Abstract][Full Text] [Related]
11. Safety and Oncological Outcomes of Bevacizumab Therapy in Patients With Advanced Colorectal Cancer and Self-expandable Metal Stents.
Pacheco-Barcia V; Mondéjar R; Martínez-Sáez O; Longo F; Moreno JA; Rogado J; Donnay O; Santander C; Carrato A; Colomer R
Clin Colorectal Cancer; 2019 Sep; 18(3):e287-e293. PubMed ID: 31262698
[TBL] [Abstract][Full Text] [Related]
12. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.
Pander J; Gelderblom H; Antonini NF; Tol J; van Krieken JH; van der Straaten T; Punt CJ; Guchelaar HJ
Eur J Cancer; 2010 Jul; 46(10):1829-34. PubMed ID: 20418097
[TBL] [Abstract][Full Text] [Related]
13. Palliative self-expandable metal stents for acute malignant colorectal obstruction: clinical outcomes and risk factors for complications.
Han JP; Hong SJ; Kim SH; Choi JH; Jung HJ; Cho YH; Ko BM; Lee MS
Scand J Gastroenterol; 2014 Aug; 49(8):967-73. PubMed ID: 24874189
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
[TBL] [Abstract][Full Text] [Related]
15. [Effect of KRAS mutation on efficacy of Cetuximab combined with chemotherapy in advanced colorectal cancer patients].
Pu XX; Deng YH; Xu F; Xiao J; Guo HQ; Huang H; Tian Y; He YJ; Lin TY
Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Nov; 12(6):594-7. PubMed ID: 19921572
[TBL] [Abstract][Full Text] [Related]
16. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
17. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
Tejpar S; Celik I; Schlichting M; Sartorius U; Bokemeyer C; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3570-7. PubMed ID: 22734028
[TBL] [Abstract][Full Text] [Related]
18. [Correlation analysis between abundance of K-ras mutation in plasma free DNA and its correlation with clinical outcome and prognosis in patients with metastatic colorectal cancer].
Bai YQ; Liu XJ; Wang Y; Ge FJ; Zhao CH; Fu YL; Lin L; Xu JM
Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):666-71. PubMed ID: 24332053
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of cetuximab+irinotecan for unresectable advanced or recurrent colorectal cancer].
Soda H; Nemoto H; Akatsuka S; Arioka H; Shimada K; Ito T; Takinishi Y; Egawa M; Nagashima A; Kenmochi T; Sasaki T; Azuma T; Koizumi W; Hibi K
Gan To Kagaku Ryoho; 2013 May; 40(5):605-8. PubMed ID: 23863582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
